|  |  |  |  |
| --- | --- | --- | --- |
| OS | | PFS | |
| Chemo | 0.10 | Chemo | 0.10 |
| Camre-chemo | 0.54 | Camre-chemo | 0.69 |
| Pem-chemo | 0.49 | Pem-chemo | 0.53 |
| Sint-chemo | 0.67 | Sint-chemo | 0.70 |
| Nivo-chemo | 0.47 | Nivo-chemo | 0.32 |
| Tori-chemo | 0.73 | Tori-chemo | 0.65 |

Supplementary File 6. Surface Under the Cumulative Ranking (SUCRA). The preferred probability ranking of OS and PFS for each intervention. For OS, toripalimab plus chemotherapy may be considered the best treatment. For PFS, sintilimab plus chemotherapy may be considered the best treatment, followed by sintilimab plus chemotherap and toripalimab plus chemotherapy, consistent with the order probability of pros and cons results. SUCRA values range from 1, being the best without uncertainty, to 0, being the worst without uncertainty.